This small molecule is being tested by scientists at the ALS Therapy Development Institute for its potential to help support the unfolded protein response in ALS patients by specifically targeting the SOD1 protein.
This is a complex approach which has proved unsuccessful in the past; however, we hope to show our current construct effective in cell-based tests quickly.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
Please give to ALS TDI to help us get promising treatments out of our lab and into people living with ALS.
November 28 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.